HYPE: Retatrutide is already proven more powerful than Ozempic and Mounjaro, so it is the best weight-loss treatment.
But what does the evidence actually show?
Retatrutide has produced substantial weight loss in randomised trials, including a new phase 3 publication. It has not yet been shown to beat tirzepatide in a completed published head-to-head obesity trial identified in this review. Cross-trial percentages suggest potential, but cannot establish the best treatment. Retatrutide remains investigational and is not authorised in the UK as checked immediately before this publication.
What is retatrutide?
Retatrutide is an injectable agonist at GIP, GLP-1 and glucagon receptors. The research aims to influence appetite and metabolic pathways through that combination. More receptor targets create a hypothesis to test; their number alone cannot establish better effectiveness, tolerability or long-term safety.
Ozempic contains semaglutide and is principally associated with diabetes treatment. Wegovy is the semaglutide product used in obesity research and licensed weight management. Mounjaro contains tirzepatide, which acts at GIP and GLP-1 receptors. Drug, indication and dose must be identified before comparing a headline.
What does the best current evidence show?
A late-September 2026 phase 3 paper makes older phase 2 summaries incomplete. Its primary weight analysis should also be distinguished from the larger figure in an earlier sponsor announcement.
Published weight loss reached 25.0% in the highest-dose group
Jastreboff and colleagues randomised 2,339 adults with obesity without diabetes to retatrutide or placebo for 80 weeks. Mean weight change was −17.6%, −23.7% and −25.0% at 4, 9 and 12 mg, versus −3.9% with placebo, using a treatment-regimen analysis that handles stopping treatment. Gastrointestinal events were most common. This trial establishes benefit against placebo; it did not compare tirzepatide or semaglutide.
The 28.3% figure comes from a different analysis
Lilly’s earlier TRIUMPH-1 announcement reported 28.3% at 12 mg using an efficacy estimand. That approach asks a different question from the published treatment-regimen estimate of 25.0%. Mixing analysis methods can exaggerate a comparison. The sponsor announcement also describes a selected extension, which should not be treated as the result for every randomised participant.
There is head-to-head evidence for tirzepatide versus semaglutide
An open-label randomised trial compared maximum tolerated tirzepatide with semaglutide 1.7 or 2.4 mg weekly in adults without diabetes. Mean weight change at 72 weeks was −20.2% versus −13.7%. That supports the tested tirzepatide-versus-semaglutide comparison. It does not establish a retatrutide advantage.
The catch: cross-trial rankings are provisional
The retatrutide and SURMOUNT-5 studies differ in duration, participants, comparison group, blinding and doses. A difference between their averages is an indirect observation, not a randomised treatment difference. Weight loss is also one outcome, not a complete benefit-risk assessment.
A September 2026 network meta-analysis of 58 trials suggested a high weight-loss ranking for retatrutide, but acknowledged limited direct comparisons and tolerability uncertainty. Network methods help synthesise indirect evidence; they depend on the comparability of the included trials. [4]
Lilly lists TRIUMPH-5, a direct retatrutide-versus-tirzepatide obesity study, with completed enrolment and trial dates extending to December 2026. We did not identify published results when checking this review. A study being underway does not demonstrate its answer. [5]
The retatrutide and SURMOUNT-5 trials were funded by Eli Lilly. Sponsorship does not erase randomised findings, but protocol choices, analysis and independent replication remain relevant.
Current semaglutide options complicate the headline
SURMOUNT-5 tested particular semaglutide doses. The UK now also has authorisation for a 7.2 mg Wegovy injection for eligible adults with obesity. Older 2.4 mg outcomes should not be presented as the performance of every current semaglutide option. Nor should an Ozempic diabetes dose be used as if it were an identical obesity comparison. [6]
Safety and approval status
The MHRA states that retatrutide has not been authorised for use in the UK and warns against unauthorised products. A paediatric investigation plan or a positive clinical trial is not a marketing authorisation. The latest sponsor materials still describe it as investigational; we found no regulator approval supporting ordinary patient supply. [7] Lilly’s current public information also states that it has not been approved by any regulatory agency. [8]
An online vial labelled retatrutide or research use only is not the characterised trial medicine. Identity, sterility, contamination and dose cannot be inferred from a seller’s label. Do not obtain or self-administer an unauthorised product. Clinical trial results cannot establish the safety of a counterfeit.
The phase 3 paper is assessed here from its published abstract and verified primary record. We cannot independently evaluate every supplementary analysis or uncommon adverse event from that alone. Long-term outcomes and a regulator’s benefit-risk assessment remain important.
What this means for you
Follow the research, but distinguish a large trial result from an available treatment. The published 25.0% estimate and sponsor 28.3% estimate answer different analysis questions; neither is a personal guarantee.
If you need weight-management care now, discuss licensed options with a clinician. This investigation links to research and safety information, not unauthorised suppliers. A completed direct trial would be more informative about superiority than promotional rankings.
Substantial trial weight loss. Direct superiority is unresolved, and retatrutide remains investigational.
Research & Sources
1. Jastreboff et al. (29 September 2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. NEJM. TRIUMPH-1. Published abstract assessed.
2. Eli Lilly (21 May 2026). TRIUMPH-1 sponsor announcement. Efficacy-estimand results and selected extension; not an independent review.
3. Aronne et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. SURMOUNT-5. Published abstract assessed.
4. Comparative efficacy and safety of GLP-1 based drugs for weight loss: network meta-analysis (2026). BMJ Medicine. Published abstract assessed.
5. Eli Lilly trial record. TRIUMPH-5, NCT06662383: retatrutide compared with tirzepatide.
6. MHRA (14 April 2026). Single-dose 7.2 mg Wegovy pen approval for eligible adults with obesity.
7. MHRA. No summer shortcut for safe weight loss: unauthorised retatrutide warning. Status rechecked October 2026.
8. Eli Lilly. What to know about retatrutide. Current investigational status, checked immediately before publication.
Evidence reviewed: October 2026
This targeted editorial review assessed research available on 13 October 2026; it is not an exhaustive systematic review. Abstract-only assessments are identified in the sources. Evidence vs Hype provides education, not individual diagnosis or treatment. Featured artwork is conceptual, not a study result. No commercial product was selected or endorsed for this investigation.